Ribomic

Ribomic Gross Margin

The Gross Margin of Ribomic (4591.T) as of Oct 30, 2026 is -33.17 %. In the previous year, Gross Margin was 56.43 % — a change of -158.77% (lower).

Gross Margin

-33.17 %

YoY

-158.77%

Last updated:

Gross Margin of Ribomic is 2026 -33.17 % . Gross Margin of Ribomic was 2025 56.43 % . It decreases by -158.77% lower compared to the previous year.

Ribomic's gross margin stands at -33.2%, down from 100.0% several years earlier.

The Ribomic Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
98.88 JPY
Jan 1, 2019
88.06 JPY
Jan 1, 2020
99.68 JPY
Jan 1, 2021
100.00 JPY
Jan 1, 2022
100.00 JPY
Jan 1, 2023
100.00 JPY
Jan 1, 2025
56.43 JPY
Jan 1, 2026
-33.17 JPY
The Ribomic Gross Margin history
YEARGross MarginYoY
-33.17 %-158.77%
56.43 %-43.57%
100.00 %0.00%
100.00 %0.00%
100.00 %+0.32%
99.68 %+13.20%
88.06 %-10.94%
98.88 %-0.30%
99.18 %-0.08%
99.25 %+3.30%
96.08 %+4.89%
91.60 %+9,683.73%
0.94 %+13.76%
0.82 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ribomic Stock analysis

What does Ribomic do? Ribomic, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for therapeutic applications. Headquartered in Minato-Ku, Tokyo-To, the company utilizes its workforce of 25 full-time employees to drive its drug discovery operations, which are structured into self discovery and co-discovery divisions. This operational framework allows the firm to focus on advancing RNA aptamer technologies for medical use. The Self Drug Discovery division develops aptamers and licenses these results to pharmaceutical companies, generating revenue through intellectual property transfers. Meanwhile, the Co-Discovery division collaborates with alliance pharmaceutical companies researching aptamer pharmaceuticals. This segment earns research expenses paid by the alliance partners for the shared portion of the co-discovery business, creating a dual revenue stream based on licensing and collaborative research fees. Ribomic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ribomic stock

Gross Margin of Ribomic is -33.17 % in 2026.

Gross Margin of Ribomic changed from 56.43 % to -33.17 %, representing a -158.77% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Ribomic since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Ribomic with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Ribomic

All Key Metrics — Ribomic